openPR Logo
Press release

New Research Published– CerviLenz® Compared to Fetal Fibronectin

12-08-2010 09:30 AM CET | Health & Medicine

Press release from: CerviLenz

CerviLenz logo

CerviLenz logo

CLEVELAND, OH – December 1, 2010

CerviLenz is a simple, new medical device that measures vaginal cervical length objectively. In November, the Journal of Maternal-Fetal and Neonatal Medicine published the results of a study conducted by Richard Burwick, MD at Harbor-UCLA Hospital in Los Angeles, CA, examining the utility of CerviLenz in predicting preterm birth in women with symptoms of preterm labor. The study sought to compare cervical length (CL) measured by CerviLenz to the fetal fibronectin (fFN) test, an expensive laboratory test.

The study demonstrated that in women with symptoms of preterm labor, CerviLenz performs equivalently to the fFN test in predicting preterm birth within 7 days. The authors concluded: “…we recommend that CerviLenz be considered as a primary modality in place of digital exam or fFN testing in screening women for CL and preterm labor.”

“These research findings are very consistent with what I‟ve seen in clinical practice,” said Edwin Ramirez, MD, an obstetrician/gynecologist at a large hospital in Lancaster, California. “We‟ve been using CerviLenz in our hospital for several months and have been very pleased with our experience. CerviLenz is easy to use, and it helps us quickly assess patients with preterm labor symptoms. With a CerviLenz measurement, we are able to make decisions about how best to manage their care, including using other assessments more selectively. For example, for a low risk patient with a closed cervix and a CerviLenz measurement longer than 30 mm, I typically do not run the fFN test. We are definitely seeing the positive impact on triage time and cost that Dr. Burwick‟s research suggests.”

Dean Koch, President and CEO of Cervilenz Inc., said, “We are very excited to see the study published by Dr. Burwick and his team. Pregnant women with symptoms of preterm labor make up the majority of Labor and Delivery triage patients in most hospitals, and pose a difficult clinical dilemma for the clinician. We are very proud to see how CerviLenz performed in this study. Our motto is „Confident Decisions Faster‟ – Dr. Burwick‟s work demonstrates that CerviLenz delivers exactly that.”

# # #

Cervilenz Inc. is the manufacturer and distributor of CerviLenz®, a low cost, single use medical device that measures vaginal cervical length. Dedicated to making a difference in the world of prematurity, Cervilenz Inc. donates a portion of revenue to charitable organizations that advance maternal and fetal health worldwide. The company headquarters is in the beautiful village of Chagrin Falls – a suburb of Cleveland, Ohio. For more information, please visit cervilenz.com or contact Melanie Sweeney, Director of Marketing (440.337.4253 or melanie@cervilenz.com).

Media Inquiries:
Melanie Sweeney
100 N. Main Street, Suite 300
Chagrin Falls, OH 44022
(P) 440.337.4253
(E) melanie@cervilenz.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release New Research Published– CerviLenz® Compared to Fetal Fibronectin here

News-ID: 154530 • Views:

More Releases from CerviLenz

New Data for the CerviLenz® Device Presented at the 10th World Congress of Maternal and Neonatal Health
New Data for the CerviLenz® Device Presented at the 10th World Congress of Mate …
Cleveland, Ohio and Rome, Italy – December 20, 2011 Two new studies demonstrating the clinical utility of the CerviLenz® device were presented today at the 10th World Congress of Maternal and Neonatal Health in Rome, Italy. The CerviLenz device is simple to use and disposable, allowing cervical length measurement in any health care setting and providing an immediate quantitative result. The Congress sponsors include the World Health Organization, the European Association of
Cervilenz Inc. receives CE Mark and Additional International Patents for its Signature CerviLenz® Device
Cervilenz Inc. receives CE Mark and Additional International Patents for its Sig …
CLEVELAND, OH – November 17, 2011 Cervilenz Inc. recently received its CE Mark and ISO 13485 Certification for the CerviLenz® device. This innovative medical device is used to measure vaginal cervical length to help obstetricians identify and manage pregnant women at high risk for premature birth. Cervilenz Inc. also added to its already robust patent portfolio for the device. The company now holds 12 issued patents, including 5 in the United States,
Interplex Medical Exhibit at MEDICA 2011 Features The CerviLenz® Device Used fo …
Milford OH – November 14, 2011 - Interplex Medical, LLC, an FDA-registered, ISO 13485-certified company that designs and manufactures medical products for OEM customers, will display a variety of newly developed components, subsystems and finished products at MEDICA 2011, including an innovative device it helped develop for Cleveland-based Cervilenz Inc. The Interplex Medical exhibit at Medica will be located in the North America Pavilion at Booth D32-13 in
Cervilenz Inc. Exhibits at the 2011 Annual Clinical Meeting
Cervilenz Inc. Exhibits at the 2011 Annual Clinical Meeting
Cervilenz Inc. is exhibiting at the 59th Annual Clinical Meeting (ACM) of The American College of Obstetricians and Gynecologists from May 2nd to May 4th, 2011 in Washington D.C. Cervilenz Inc. can be found at Booth #2528. CerviLenz® measures cervical length during pregnancy. A short cervix is a powerful predictor of preterm birth risk. This simple tool gives obstetricians and midwives a quick, easy way to measure the

All 5 Releases